Retinal vascular occlusion

Summary

Retinal vascular occlusion (MONDO:0002089) is a disease and 3 clinical trials. Top therapeutic interventions include brolucizumab. A subtype of retinal vascular disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	retinal vascular occlusion
Mondo ID	MONDO:0002089
DOID	DOID:1729
ICD-10-CM	H34
NCIT	C34980
SNOMED CT	73757007
UMLS	C0035326
MedGen	19762
Anatomy (UBERON)	UBERON:0000966
Is cancer (heuristic)	no

Also known as: retinal vascular occlusion · retinal vascular occlusion, unspecified

Disease family

This is a subtype of retinal vascular disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vascular occlusion

Related subtypes (11): retinal microaneurysm, retinal hemangioblastoma, retinal telangiectasia, diabetic retinopathy, retinal vasculitis, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations, familial retinal arterial macroaneurysm, vasoproliferative tumor of retina, exudative vitreoretinopathy, arteriosclerotic retinopathy, perifoveal exudative vascular anomalous complex

Subtypes (2): retinal artery occlusion, retinal vein occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01291862	Not specified	UNKNOWN	Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion
NCT01939119	Not specified	UNKNOWN	Body-fluid Balance and Drinking Habits in Patients With Retinal Vascular Occlusion
NCT05657158	Not specified	COMPLETED	Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BROLUCIZUMAB	4	1